EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights • Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026; • Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026; • Cash balance of $0.3 million at quarter and year end; • Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026; • Recognized an adjusted EBITDA loss of $0.1 million for …
Open exhibit ↗Current Report · Items 2.02, 8.01, 9.01 · 8-K
CV Sciences, Inc.
CVSIOTCEQUITYCurrent
Results of Operations and Financial Condition · Other Events
Item 2.02 Results of Operations and Financial Conditions The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.
Press release in this filing
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results →Company context
CV Sciences, Inc. (OTCQB:CVSI) is a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products. The Company's products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for